The US Amlodipine Besylate market witnessed a notable upward movement in April as tightening supply conditions, regulatory disruptions, and changing procurement strategies collectively strengthened CFR pricing trends. Simultaneously, environmental compliance-related shutdowns across Jiangsu province in China curtailed regional API production, preventing Chinese suppliers from fully compensating for reduced Indian output of Amlodipine Besylate. On the demand side, distributors accelerated inventory rebuilding after Q* destocking linked to Inflation Reduction Act negotiations, while several US hospital procurement groups advanced a portion of their Q* tenders into April. This shift substantially increased short-term inquiries for Amlodipine Besylate, tightening spot market availability further. In addition, elevated Trans-Pacific container freight rates and extended Los Angeles port dwell times compressed landed inventories of Amlodipine Besylate, enabling exporters and traders to maintain firmer CFR offers throughout the month.
Demand from the pharmaceutical sector, particularly cardiovascular generic manufacturers and finished-dosage formulators, remained the primary support...
Leave a Comment
Comments (0)